Protective immunity against porcine circovirus 2 in mice induced by a gene‐based combination vaccination

Kandan, A.; Kuo, Tsun-Yung; Lan, Chun-Wen; Yu, Hsiu-Hui; Wang, Pei-Hsueh; Chen, Yu-San; Chen, Gabriel Hsu-Chung; Yang, Ning‐Sun

doi:10.1002/jgm.1300

Cited by 16 publications

(9 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct injection of plasmid DNA has been used as a promising approach to protect animals and humans against pathogens (34,35). DNA vaccines against PCV2 have been investigated, which often have limited efficacy and need two or three immunizations to achieve a good level of immunity (1,3,8). DNA vaccines often have limited efficacy.…”

mentioning

confidence: 99%

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Chen

Wang

et al. 2014

Viral Immunology

View full text Add to dashboard Cite

In this study, two recombinant plasmids containing the ORF2 gene of porcine circovirus type 2 (PCV2) with or without porcine interleukin-18 (IL-18) were constructed and evaluated for their ability to protect piglets against PCV2 challenge. Transient expression of the plasmids in PK-15 cells could be detected using Western blot. Piglets were given two intramuscular immunizations 3 weeks apart and were challenged with a virulent Wuzhi strain of PCV2 at 42 days after the initial immunization. All animals vaccinated with pBudCE4

show abstract

mentioning

confidence: 99%

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Chen

Wang

et al. 2014

Viral Immunology

View full text Add to dashboard Cite

show abstract

“…The recombinant vaccines for PCV2 infection, in majority, use genetical manipulation in the sequence of ORF2 nucleotide that contains a region where the immunogenic epitopes of the virus are scripted [57][58][59][60]. Certain studies have used the strategy of DNA vaccine using ORF2 as the immunogen [61][62][63][64]. The DNA vaccines can be injected with the use of the traditional syringes or inoculated by the use of gene guns.…”

Section: Experimental Vaccinesmentioning

confidence: 99%

Porcine Circovirus 2: Immunopathogenesis and Recent Developments in Vaccines

Júnior¹,

Carvalho²,

Bulos³

et al. 2012

WJV

View full text Add to dashboard Cite

Porcine circovirus 2 (PCV2) is currently considered an important etiologic agent of swine and its infection has potentially serious economic impact on the swine industry worldwide. This virus is frequently associated with postweaning multisystemic wasting syndrome (PMWS), and also with other clinical conditions such as porcine dermatitis and nephropathy syndrome (PDNS), late-term abortions, reproductive failure in sows, proliferative and necrotizing pneumonia and congenital tremors. The term porcine circovirus-associated disease (PCVAD) is currently used to refer to any of these diseases when they are associated with PCV2 infection. The PCV2 was recognized as a pathogen in 1997, and many questions regarding its biology and pathogenesis remain unanswered. Currently, some studies have shown the production of new vaccine candidates and field efficacy testing of commercial vaccines. This review discusses some major points concerned with immunopathogenesis and vaccines for PCV2 infection

show abstract

“…Although studies were developed in both preclinical and clinical stages for human and veterinary applications, a fixed prime-boost regimen is still not available. Recent publications from the veterinary field demonstrated that combination of a gene gun-mediated naked DNA vector as priming and MVA as booster in mice is an attractive line of attack against porcine circovirus type 2 (PCV2) [112]. A vaccination scheme for highly pathogenic avian influenza H5N1 (AsHP H5N1) virus revealed that priming with a fowlpox-vectored vaccine followed by a boost with inactivated vaccine stimulated a broader protection than two administrations of a fowlpox recombinant (vFP-H5 Asia) [113].…”

Section: What To Expect From the Prime-boost Approach?mentioning

confidence: 99%

DNA vaccines for targeting bacterial infections

Ingolotti

Kawalekar

Shedlock

et al. 2010

Expert Review of Vaccines

117

View full text Add to dashboard Cite

DNA vaccination has been of great interest since its discovery in the 1990s due to its ability to elicit both humoral and cellular immune responses. DNA vaccines consist of a DNA plasmid containing a transgene that encodes the sequence of a target protein from a pathogen under the control of a eukaryotic promoter. This revolutionary technology has proven to be effective in animal models and four DNA vaccine products have recently been approved for veterinary use. Although few DNA vaccines against bacterial infections have been tested, the results are encouraging. Because of their versatility, safety and simplicity a wider range of organisms can be targeted by these vaccines, which shows their potential advantages to public health. This article describes the mechanism of action of DNA vaccines and their potential use for targeting bacterial infections. In addition, it provides an updated summary of the methods used to enhance immunogenicity from codon optimization and adjuvants to delivery techniques including electroporation and use of nanoparticles.Keywords bacterial vaccine; cellular and humoral immune responses; DNA vaccine; molecular adjuvants Times have changed since Edward Jenner immunized James Phipps against smallpox in 1796 and created what years later became known as a vaccine [1]. From the first live-attenuated or killed vaccines to the era of DNA vaccines in the early 1990s, molecular biology and microbiology have aided medical research in the development of vaccines against infectious diseases, cancer, allergies and autoimmune diseases by inducing rapid and robust immune responses or by creating immune tolerance [2]. From the time of Jenner's first vaccine until the present day, there have been over 60 licensed vaccines in the USA. These vaccines come in many forms: killed microorganisms, live-attenuated microorganisms, subunits, conjugate vaccines or toxoids. Although there are no US FDA-approved DNA vaccines for use in humans, they are the newest vaccine platform currently in development and have already had success in veterinary medicine [3][4][5][6][7][8].© 2010 Expert Reviews Ltd † Author for correspondence: Tel.: +1 215 349 8591, Fax: +1 215 573 9436, dbweiner@mail.med.upenn.edu. Financial & competing interests disclosureThe authors declare possible commercial conflicts, which may include advising, consulting and collaboration, with Wyeth, Inovio, BMS, Virxsys, Ichor, Merck, Althea, Johnson & Johnson and Aldeveron. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. NIH Public Access Author ManuscriptExpert Rev Vaccines. Author manuscript; available in PMC 2011 May 1. Published in final edited form as:Expert Rev Vaccines. 2010 July ; 9(7): 747-763. doi:10.1586/erv.10.57. NIH-PA Author ManuscriptNIH-PA Author Manuscript N...

show abstract

Protective immunity against porcine circovirus 2 in mice induced by a gene‐based combination vaccination

Abstract: This prime-boost vaccination strategy, using a gene gun for DNA priming and recombinant MVA for boosts, may be an attractive vaccine strategy against PCV2 infection in swine.

Cited by 16 publications

References 58 publications

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Porcine Circovirus 2: Immunopathogenesis and Recent Developments in Vaccines

DNA vaccines for targeting bacterial infections

Contact Info

Product

Resources

About